Pharmaceutical - Swedish Orphan Biovitrum


Current filters:

Swedish Orphan Biovitrum

Popular Filters

SOBI updates on Kepivance and SOB1002 development

SOBI updates on Kepivance and SOB1002 development


At its Capital Market Day event on November 5, Swedish Orphan Biovitrum shared information regarding…

Inflammatory diseasesKepivanceKiobrinaOncologyPharmaceuticalResearchSOB1002SobiSwedish Orphan Biovitrum

SOBI gains rights to distribute Ravicti in Middle East


Swedish Orphan Biovitrum says Hyperion Therapeutics has granted it exclusive rights to distribute its…

Genito-urinaryHyperion TherapeuticsLicensingPharmaceuticalRavictiRest of the WorldSobiSwedish Orphan Biovitrum

SOBI restructures Kineret and Kepivance deals


Swedish Orphan Biovitrum (STO: SOBI) said this morning that it has acquired the full rights to develop…

AmgenAnti-Arthritics/RheumaticsBiotechnologyKepivanceKineretLicensingOncologyPharmaceuticalRare diseasesSwedish Orphan Biovitrum

SOBI files for Orfadin oral suspension with EMA


Swedish Orphan Biovitrum (STO: SOBI) said this morning (August 22) that the company's application for…

EuropeOrfadinPharmaceuticalRare diseasesRegulationSwedish Orphan Biovitrum

Auxilium and SOBI collaborate on Xiapex


USA-based Auxilium Pharmaceuticals (Nasdaq: AUXL) and Swedish Orphan Biovitrum (STO: SOBI) have entered…

Auxilium PharmaceuticalsEuropeLicensingPharmaceuticalRare diseasesRest of the WorldSwedish Orphan BiovitrumXiapex

New data support safety and efficacy of Biogen Idec and SOBI's Alprolix


US biotech firm Biogen Idec (Nasdaq: BIIB) and Swedish Orphan Biovitrum (STO: SOBI) yesterday presented…

AlprolixBiogen IdecBiotechnologyPharmaceuticalResearchSwedish Orphan Biovitrum

SOBI gets FDA approval to manufacture substance for Kineret with partner Boehringer Ingelheim


Swedish Orphan Biovitrum (STO: SOBI) said today (June 11) that it has received approval from the US Food…

Boehringer IngelheimInflammatory diseasesKineretNorth AmericaPharmaceuticalProductionRegulationSavient PharmaceuticalsSwedish Orphan Biovitrum

SOBI links with Savient for co-promotion of Kineret in USA


Swedish Orphan Biovitrum (STO: SOBI) says it has entered into an agreement with USA-based Savient Pharmaceuticals…

Anti-Arthritics/RheumaticsInflammatory diseasesKineretLicensingMarkets & MarketingNorth AmericaPharmaceuticalSavient PharmaceuticalsSobiSwedish Orphan Biovitrum

SOBI gains distribution rights for Megace, Monopril, Cefzil and Duricef from PharmaSwiss


Swedish Orphan Biovitrum (STO: SOBI) says that it has entered into a distribution agreement with privately-held…

Antibiotics and Infectious diseasesCardio-vascularCefzilDuricefEuropeLicensingMegaceMonoprilOncologyPharmaceuticalPharmaSwissSobiSwedish Orphan Biovitrum

SOBI gains EMA approval for change of Kineret producer; Novartis drops NIC002 project


Swedish Orphan Biovitrum (STO: SOBI) has received approval from the European Medicines Agency for the…

BiotechnologyBoehringer IngelheimCytos BiotechnologyKineretLicensingNIC002NovartisPharmaceuticalProductionRegulationSwedish Orphan Biovitrum

News briefs from Sanofi, Biogen/SOBI and Novartis


French drug major Sanofi (Euronext: SAN) and subsidiary Genzyme have reported results from pivotal studies…

AgrippalBiogen IdecBiotechnologyFluadLemtradaNeurologicalNovartisPharmaceuticalRegulationResearchSanofiSwedish Orphan BiovitrumVaccines

Positive Ph III results for Biogen Idec and SOBI's hemophilia B agent


US biotech firm Biogen Idec (Nasdaq: BIIB) and partner Swedish Orphan Biovitrum (STO: SOBI) have announced…

Biogen IdecBiotechnologyEuropeNorth AmericaPharmaceuticalRare diseasesRegulationResearchrFIXFcSobiSwedish Orphan Biovitrum

Sobi and Biogen Idec flesh out details of hemophilia programs


Stockholm-based Swedish Orphan Biovitrum (STO: SOBI) and US biotech company Biogen Idec (Nasdaq: BIIB)…

Biogen IdecBiotechnologyCardio-vascularLicensingPharmaceuticalSwedish Orphan Biovitrum

Sobi buys rights to novel neonatology treatment


Stockholm-based Swedish Orphan Biovitrum (STO: SOBI) has signed a global licensing agreement with the…

BumetanideCardio-vascularLicensingNeurologicalOnly for Children PharmaceuticalsPharmaceuticalSwedish Orphan Biovitrum

Pharming extends Ruconest deal with SOBI


Netherlands-based biotech firm Pharming Group NV (Euronext: PHARM) has extended its existing agreement…

BiotechnologyEuropeLicensingPharmaceuticalPharmingRare diseasesRest of the WorldRhucinRuconestSwedish Orphan Biovitrum

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top